dkk 4.000 <%= Resources.Global.txtDown %>
Updated 24/05/2018
Change % -1.23% Stock price decreasing
Change -0.05 Stock price decreasing
Volume 79,200
High DKK 4.070
Low DKK 4.000
Open DKK 4.030
ISIN DK0010224666
Prev close DKK 4.050
# of shares 24.55M
Market cap 98.22M DKK
Intraday

Market closed
NeuroSearch A/S
Market is closed, opens at 08:00
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  4.00 -9.1% Stock price decreasing 29.4% Stock price increasing -17.0% Stock price decreasing 11.1% Stock price increasing 12.4% Stock price increasing
Key Figures (m DKK)
Turnover
EBIT
Net Profit
Equity
Balance
2016
0
-6,300
22,815
71,383
79,421
2015
0
-6,488
-5,538
72,400
78,594
2014
0
-13
-8
78
84
2013
29
-10
12
88
92
2012
121
-290
-276
81
208
2011
0
-383
-678
321
841
2010
69
-328
-259
994
1,392
2009
85
-356
-287
1,174
0
2008
67
-366
-382
0
0
2007
115
-253
-268
1,121
0
Powered by TradingView

Related

Latest 1 week 1 month 3 months 6 months 1 year
YTD
 
Competitors Open
 
Vivus Inc 0.9346 49.7% Stock price increasing 159.6% Stock price increasing 100.4% Stock price increasing 42.1% Stock price increasing -16.6% Stock price decreasing 86.0% Stock price increasing
 
H Lundbeck A/S 428.40 0.5% Stock price increasing 22.9% Stock price increasing 34.3% Stock price increasing 27.4% Stock price increasing 22.4% Stock price increasing 36.0% Stock price increasing

Company profile

NeuroSearch is a biopharmaceutical company specializing in central nervous diseases (CNS). The company has two businesses: Specialty Pharma, focusing on completing the development and marketing of their first product; Huntexil against Huntington's disease. The second business NsDiscovery, manages early drug discoveries. The drug Tesofensine against obesity is also ready for clinical phase III and NeuroSearch seeks a partner for completion of development. Main risk factor for drug development is financial risk. The company has several drug discovery- and development collaborations with major pharmaceutical companies such as Abbott, Eli Lilly and Janssen Pharmaceuticals. The cooperation entitles NeuroSearch to premarketing milestone payments on each compound developed and potentially royalties if the drug is commercialized.

Peers

Instruments Last Change  
Vivus Inc 0.9346 5.6% Stock price increasing
69,0,6,12,23,33,61,61,65,84
Lundbeck A/S 428.40 0.7% Stock price increasing
96,98,98,98,98,99,98,98,96,0

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
25 May 2018 00:20:57
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180524.2 - EUROWEB3 - 2018-05-25 01:20:57 - 2018-05-25 00:20:57 - 1000 - Website: OKAY